PAPER Li Z, Wang X, Wang X, Yi X, Wong YK, Wu J, Xie F, Hu D, Wang Q, Wang J, Zhong T

Research progress on the role of extracellular vesicles in neurodegenerative diseases.

Transl Neurodegener. 2023 Sep 11;12(1):43. PubMed.

PAPER Zhou ZD, Yi LX, Wang DQ, Lim TM, Tan EK

Role of dopamine in the pathophysiology of Parkinson's disease.

Transl Neurodegener. 2023 Sep 18;12(1):44. PubMed.

PAPER Zhu L, Li S, Li XJ, Yin P

Pathological insights from amyotrophic lateral sclerosis animal models: comparisons, limitations, and challenges.

Transl Neurodegener. 2023 Sep 20;12(1):46. PubMed.

PAPER Richardson PJ, Smith DP, de Giorgio A, Snetkov X, Almond-Thynne J, Cronin S, Mead RJ, McDermott CJ, Shaw PJ

Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis.

Transl Neurodegener. 2023 Oct 12;12(1):47. PubMed.

PAPER Lepiarz-Raba I, Gbadamosi I, Florea R, Paolicelli RC, Jawaid A

Metabolic regulation of microglial phagocytosis: Implications for Alzheimer's disease therapeutics.

Transl Neurodegener. 2023 Oct 31;12(1):48. PubMed.

PAPER Mo H, Kim J, Kim JY, Kim JW, Han H, Choi SH, Rim YA, Ju JH

Intranasal administration of induced pluripotent stem cell-derived cortical neural stem cell-secretome as a treatment option for Alzheimer's disease.

Transl Neurodegener. 2023 Nov 9;12(1):50. PubMed.

PAPER Gao Y, Wang Y, Lei H, Xu Z, Li S, Yu H, Xie J, Zhang Z, Liu G, Zhang Y, Zheng J, Wang JZ

A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau.

Transl Neurodegener. 2023 Nov 10;12(1):51. PubMed. Correction.

PAPER Zou P, Wu C, Liu TC, Duan R, Yang L

Oligodendrocyte progenitor cells in Alzheimer's disease: from physiology to pathology.

Transl Neurodegener. 2023 Nov 14;12(1):52. PubMed.

PAPER Faridar A, Eid AM, Thome AD, Zhao W, Beers DR, Pascual MB, Nakawah MO, Roman GC, Davis CS, Grundman M, Masdeu JC, Appel SH

A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's disease.

Transl Neurodegener. 2023 Nov 16;12(1):54. PubMed.

PAPER Wang X, Xie J, Tan L, Lu Y, Shen N, Li J, Hu H, Li H, Li X, Cheng L

N6-methyladenosine-modified circRIMS2 mediates synaptic and memory impairments by activating GluN2B ubiquitination in Alzheimer's disease.

Transl Neurodegener. 2023 Nov 28;12(1):53. PubMed.

PAPER Tallon C, Bell BJ, Malvankar MM, Deme P, Nogueras-Ortiz C, Eren E, Thomas AG, Hollinger KR, Pal A, Mustapic M, Huang M, Coleman K, Joe TR, Rais R, Haughey NJ, Kapogiannis D, Slusher BS

Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer's disease mouse model.

Transl Neurodegener. 2023 Dec 4;12(1):56. PubMed.

PAPER Shen T, Vogel JW, Duda J, Phillips JS, Cook PA, Gee J, Elman L, Quinn C, Amado DA, Baer M, Massimo L, Grossman M, Irwin DJ, McMillan CT

Novel data-driven subtypes and stages of brain atrophy in the ALS-FTD spectrum.

Transl Neurodegener. 2023 Dec 7;12(1):57. PubMed.

PAPER Zhang M, Zhang Z, Li H, Xia Y, Xing M, Xiao C, Cai W, Bu L, Li Y, Park TE, Tang Y, Ye X, Lin WJ

Blockage of VEGF function by bevacizumab alleviates early-stage cerebrovascular dysfunction and improves cognitive function in a mouse model of Alzheimer's disease.

Transl Neurodegener. 2024 Jan 3;13(1):1. PubMed.

PAPER Gebril HM, Aryasomayajula A, de Lima MR, Uhrich KE, Moghe PV

Nanotechnology for microglial targeting and inhibition of neuroinflammation underlying Alzheimer's pathology.

Transl Neurodegener. 2024 Jan 4;13(1):2. PubMed.

PAPER Qi XH, Chen P, Wang YJ, Zhou ZP, Liu XC, Fang H, Wang CW, Liu J, Liu RY, Liu HK, Zhang ZX, Zhou JN

Increased cysteinyl-tRNA synthetase drives neuroinflammation in Alzheimer's disease.

Transl Neurodegener. 2024 Jan 8;13(1):3. PubMed.